- Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
- Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
- Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
- Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
More ▼
Key statistics
On Friday, Catalyst Pharmaceuticals Inc (CPRX:NAQ) closed at 15.19, -13.18% below its 52-week high of 17.50, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.36 |
---|---|
High | 15.38 |
Low | 14.97 |
Bid | 15.03 |
Offer | 15.58 |
Previous close | 15.31 |
Average volume | 1.78m |
---|---|
Shares outstanding | 118.12m |
Free float | 110.78m |
P/E (TTM) | 28.43 |
Market cap | 1.81bn USD |
EPS (TTM) | 0.5384 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼